Baseline E138 reverse transcriptase resistance-associated mutations in antiretroviral-naive HIV-infected patients

AIDS

Volumn 26, Issue 9, 2012, Pages 1181-1182

  Siegel, Marc O ^a   Swierzbinski, Matthew ^a   Kan, Virginia L ^a,b   Parenti, David M ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS RILPIVIRINE PLUS TENOFOVIR DISOPROXIL; RILPIVIRINE; VIRUS RNA;

CD4 LYMPHOCYTE COUNT; DRUG SUBSTITUTION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INCIDENCE; LETTER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT RESPONSE;

DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; NITRILES; PYRIMIDINES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; VIRAL LOAD;

EID: 84861499172     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835393e9     Document Type: Letter

References (5)

1. Reinheimer C, Doerr HW, Stürmer M. Prevalence of TMC278 (rilpivirine) associated mutations in the Frankfurt Resistance Database. J Clin Virol 2012; 53:248-250; Epub 2011 Dec 30.
2. Rimsky L, Vingerhoets J, Van Eygen V, Eron J, Clotet B, Hoogstoel A, et al. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. J Acquir Immune Defic Syndr 2012; 59:39-46.
3. Kulkarni R, Babaoglu K, Lansdon EB, Rimsky L, Van Eygen V, Picchio G, et al. The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness. J Acquir Immune Defic Syndr 2012; 59:47-54.
4. Haddad M, Napolitano LA, Paquet AC, Evans MC, Petropoulos CJ, Whitcomb J, et al. Impact of HIV-1 Reverse Transcriptase E138 Mutations on Rilpivirine Drug Susceptibility. Final Program of the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, Illinois; 2011: P-371.
5. Johnson VA, Calvez V, Günthard HF, Paredes R, Pillay D, Shafer R, et al. 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 2011; 19:156-164.